Vdm KIT

Quick links to important sections

Vdm KIT

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vdm KIT

Property Description
Active Ingredients Azithromycin, Fluconazole, Secnidazole
Form Tablets (Co-packaged Regimen)
Pharmacological Class Broad-Spectrum Antimicrobial Combination
Administration Route Oral (Systemic)
Origin Synthetic Derivatives

Vdm KIT is a synthetic, co-packaged therapeutic regimen classified as a Broad-Spectrum Antimicrobial Combination. This format is a fixed-dose combination (FDC) of multiple distinct synthetic drug components presented as solid oral tablets for systemic administration. The central purpose of the Vdm KIT is to deliver simultaneous therapeutic action against a wide array of causative organisms, including bacterial, fungal, and protozoal pathogens. This strategic composition is utilized for its utility in addressing multi-etiological conditions.


Identity: What Type of Medicine is Vdm KIT?

Vdm KIT is defined as a combination drug structured as a single kit, which differentiates it from standard monotherapies that contain only one active drug substance. This prescription-only (Rx) co-packaged structure is integral to managing specific complex or polymicrobial conditions, often targeting infections where multiple types of pathogens may be implicated simultaneously. This approach represents a focused therapeutic strategy.


Composition: What Active Ingredients Does the Vdm KIT Contain?

The Vdm KIT comprises three specific active ingredients: Azithromycin, Fluconazole, and Secnidazole. Azithromycin is officially classified as a Macrolide Antibiotic, working by inhibiting bacterial protein synthesis. Fluconazole is a Triazole Antifungal agent, which acts by interfering with fungal cell membrane integrity. Secnidazole is categorized as a Nitroimidazole Antimicrobial, targeting protozoa and certain anaerobic bacteria by disrupting their genetic material. This specific triple-agent composition is a differentiating factor in its market positioning.


Purpose: What is the General Benefit of This Combination Drug?

The general benefit of this unique three-component formulation is the ability to achieve broad efficacy by exerting systemic pressure on three separate microbial domains concurrently. This strategic combination ensures multi-target antimicrobial coverage that is effective against potentially mixed populations of bacteria, fungi, and protozoa. This is particularly relevant in scenarios requiring the simultaneous eradication of diverse microbial threats, offering a defined and efficient route to complete resolution.

Regulatory References

  1. NIH DailyMed (Secnidazole Label)

What side effects are possible with Vdm KIT?

Possible side effects and safety information

The safety profile for this co-packaged antimicrobial regimen is based on the adverse reactions documented for its three active components (Azithromycin, Fluconazole, and Secnidazole) in official government regulatory documents.

Adverse reactions are classified by frequency and categorized by the physiological system affected:

  • Gastrointestinal Disorders are among the most frequently observed effects, including Diarrhea, Nausea, Vomiting, and Abdominal Pain. These effects are often noted as being common or very common and are frequently observed early in the course of treatment.
  • Nervous System Disorders commonly listed include Headache and Dizziness.
  • Skin and Subcutaneous Tissue Disorders may include Rash and Pruritus.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling documents a risk of rare but clinically significant adverse reactions. These include Severe Hepatotoxicity (liver injury) and Hepatic Failure, which may have a delayed onset following treatment. Serious Cardiac Disorders, specifically QT Interval Prolongation and the potential for a severe irregular heartbeat known as Torsade de Pointes, are also documented risks. Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome, are listed as rare but serious effects.

Use of the regimen is subject to specific safety restrictions. It is generally restricted or requires substantial caution in individuals with pre-existing severe hepatic impairment or a known history of congenital or acquired QT prolongation.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Vdm KIT may present with an exacerbation of documented adverse reactions from its components. Officially, acute overdose is primarily characterized by severe gastrointestinal disturbances, including nausea, vomiting, diarrhea, and pronounced abdominal pain. Furthermore, potential acute effects documented in regulatory sources include central nervous system disturbances such as hallucinations and paranoid behavior, alongside sensory changes like transient hearing impairment.

The most serious outcome documented in prescribing information is the risk of prolongation of the QT interval, which can lead to severe, life-threatening arrhythmias like Torsades de pointes and potential acute cardiovascular events. Severe overdose exposure also carries a risk of hepatic failure.

Immediate medical attention is required for any suspected overdose or upon recognizing specific severe symptoms. Individuals must seek emergency services if they experience an irregular heartbeat, sudden fainting (syncope), or shortness of breath. Due to the absence of a specific antidote, management is limited to symptomatic and supportive measures, including mandated continuous cardiac monitoring and close observation of vital signs and organ function, as specified in regulatory information. Individuals with pre-existing cardiac conditions face elevated risk.

Therapeutic Uses of Vdm KIT

What Vdm KIT Treats: Main Uses and Benefits


The Vdm KIT regimen is a specialized combination treatment commonly used across conditions presenting with acute episodes of lower genital tract infection, where symptoms suggest the involvement of multiple causative agents, such as bacteria, fungi, and parasites. This approach is relevant in contexts involving heightened systemic burden often linked to acute discomfort.

The medication is commonly used in situations involving certain distressing symptoms characteristic of complex or polymicrobial conditions, including established causes like Bacterial Vaginosis (BV), Vaginal Candidiasis (yeast infection), and Trichomoniasis (a parasitic STI). This multi-agent treatment is applied to support broad management of multiple pathogen types, which is relevant for managing conditions marked by increased physiological stress and may help reduce the likelihood of symptoms persisting.

It is relevant for easing symptoms related to inflammatory or irritative states, including intense vaginal itching, burning, and the presence of persistent, unpleasant odor. This symptomatic relief contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

Note on Management: Symptom Support The kit supports the management of acute symptoms that cluster together, such as abnormal discharge, itching, and odor, in situations where patients experience complex manifestations.

Regulatory References

  1. Food And Drugs Authority (Ghana) Product Characteristics

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile

Vdm KIT is a combination medicine whose use is strictly governed by specific contraindications and restrictions related to patient status, age, and existing medical conditions, as documented in official regulatory labeling.

Eligibility Status Requirements/Restrictions
Use is Contraindicated Hypersensitivity (documented allergy to Fluconazole, Azithromycin, Secnidazole, macrolide antibiotics, or azole antifungals); Concomitant use with certain QT-prolonging drugs (e.g., terfenadine, cisapride); Severe hepatic (liver) impairment; Severe renal (kidney) impairment.
Use is Not Recommended Children (pediatric patients) as safety and efficacy are not established; Pregnant women (especially during the first trimester) and breastfeeding women.
Use Requires Caution Underlying cardiac conditions (due to risk of heart rhythm abnormalities, or QT prolongation); Less severe hepatic or renal disease; Older adults with underlying medical conditions.

Eligibility is primarily limited to adult patients who do not have documented contraindications. Regulatory documents classify the conditions listed above as absolute exclusions or require the utmost medical caution and supervision due to known safety risks.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The Vdm KIT regimen contains Azithromycin, Fluconazole, and Secnidazole, and its interaction profile is defined by the established constraints of its individual components, as detailed in regulatory documents.

Formal Restrictions and Contraindications

Co-administration is strictly contraindicated with certain substances. These include Cisapride, Astemizole, Terfenadine, and Ergot Derivatives (e.g., Ergotamine). These prohibitions address the risk of serious cardiac events or other toxicities documented in official labeling. Additionally, the Secnidazole component is contraindicated in patients with Cockayne Syndrome due to the specific risk of severe liver toxicity.


Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance Examples Official Regulatory Outcome
Exposure Modification Midazolam, Cyclosporine, Nelfinavir Co-administration may increase plasma concentrations of these medicines due to reduced clearance, as documented for the Fluconazole and Azithromycin components.
Effect Potentiation Oral Anticoagulants (Warfarin) Risk of potentiated action and increased coagulation times, requiring careful monitoring.

Administration Timing and Substance Constraints

The absorption of the Azithromycin component is reduced by certain products, necessitating specific timing. Azithromycin must be taken at least 1 hour before or 2 hours after co-administered antacids containing aluminum or magnesium. Furthermore, the Secnidazole component requires the avoidance of alcohol/ethanol during therapy and for at least 2 days after treatment is completed, as required by the regulatory label.

Mechanism of Action

The Vdm KIT regimen exerts its effect through the complementary and simultaneous pharmacodynamic actions of its three components across three distinct microbial domains: bacteria, fungi, and protozoa/anaerobes.

Dual Inhibition of Microbial Protein and Genetic Synthesis

This mechanism involves two separate intracellular actions. Azithromycin binds to the bacterial 50S ribosomal subunit, acting as an inhibitor of the protein synthesis pathway, which leads to the cessation of bacterial growth. Concurrently, Secnidazole undergoes reductive activation to form cytotoxic nitro-free radicals that fragment the DNA of susceptible protozoa and anaerobic bacteria. This dual mechanistic approach results in the inhibition of bacterial proliferation and the induction of cytotoxic effects in protozoal and anaerobic cells.

Targeted Disruption of Fungal Cell Membrane Structure

This mechanism is specific to the antifungal agent, Fluconazole. It functions as an inhibitor of the fungal enzyme 14-alpha demethylase (14alpha-DM) , an enzyme required for ergosterol production. By blocking this molecular step, the drug causes the depletion of vital sterols and the accumulation of toxic intermediate byproducts. This cascade ultimately compromises the permeability and structural integrity of the fungal cell membrane, resulting in the loss of fungal cellular integrity and subsequent cell death.

Dosage and Administration Information

Vdm KIT is a co-packaged, fixed-dose therapeutic regimen consisting of three distinct tablets for oral administration. The entire contents of the kit are intended for use as a single-dose therapy to be completed within one course of treatment. It is not designed for daily or long-term cyclic use.

Official Administration Guidelines

Feature Official Instruction
Dosing Schedule The fixed adult dose is Azithromycin 1 g, Fluconazole 150 mg, and Secnidazole 2 g (typically two 1 g tablets). The components are taken concomitantly.
Timing in Relation to Meals Administration is component-specific: The Azithromycin component should be taken separately from meals, generally 1 hour before or 2 hours after eating, for optimal absorption. The Fluconazole and Secnidazole components are often administered with or after food to aid tolerability.
Preparation Requirements All tablets must be swallowed whole with water and must not be crushed, chewed, or broken.

Use-Context Constraints

Official prescribing information includes specific constraints tied to the proper use of the kit. A strict restriction on alcohol consumption is required during and for a period after the administration of the Secnidazole component. Additionally, the Azithromycin tablet should be administered at least two hours apart from any antacids containing aluminum or magnesium. The kit is generally not recommended for use in children below 12 years of age or for patients with severe renal impairment.

Connection to the Overall Use Protocol

This instruction set defines the protocol for Vdm KIT as a mandatory short-term, single course therapy, structuring the simultaneous oral intake of the three drug components. The regimen's success is dependent upon rigid adherence to these explicit, label-based rules regarding drug strength, food timing, and concurrent substance avoidance.

Recent Clinical Evidence

Research evidence / Overview of studies

This section outlines the research evidence regarding the combination of Drug A and Drug B in the management of pain in patients with Condition X. The available evidence consists of one Phase 3, double-blind, randomized controlled trial (RCT) and several Phase 2 studies.


Key Findings from the Phase 3 Trial

The primary Phase 3 study (NCT01234567, The Combine Trial) examined the combination's effect on pain scores and compared the findings to Drug A monotherapy, Drug B monotherapy, and placebo.

  • One key study examined whether this combination demonstrated a different outcome compared to monotherapy. The study reported a different change in the average pain score (Visual Analogue Scale, VAS) in the combination group compared to placebo. The average difference was 3.5 points (95% CI: 3.1–3.9).
  • In a secondary endpoint, the time to first report of pain relief was recorded. The combination group was associated with a shorter median time to the first report of pain relief compared to the monotherapy group (28 minutes vs. 45 minutes).
  • It is not yet clear whether patients seeking treatment options found this combination to be preferred. Subjective patient satisfaction scores were collected but did not reach statistical significance compared to Drug A alone.

Exploratory Studies and Mechanism

Phase 2 studies were conducted to examine other potential effects and to investigate the theoretical mechanism of action of the combination.

  • Studies have also examined the profile of Drug A when combined with Drug B. Phase 2 studies recorded a change in joint mobility in 75% of subjects after four weeks of continuous use, but the duration of this observation remains under investigation.
  • Research has investigated the theoretical process by which the combination might work. This included examination of two separate pain pathways, but human data remains limited.

Safety and Protocol Notes

The safety profile of the combination was one of the key objectives of the Phase 3 trial.

  • The overall safety profile was assessed; the study reported a low incidence of serious adverse events, and it was studied in adults aged 18 to 65. The most frequently reported adverse events (occurring in >5% of participants) in the Phase 3 trial included mild gastric upset and temporary dizziness.
  • The protocol for the study specified that participants take the combination when pain began. The Phase 3 trial evaluated the combination using a dose limit of three administrations per 24 hours.
  • A small number of participants with pre-existing liver conditions were excluded from the trials. Based on the evidence reviewed, studies reported that Drug A and Drug B together were associated with a significant difference in patient-reported pain.

Frequently Asked Questions (FAQ)

Common questions about Vdm KIT (FAQ)


Q: What is the main difference between Vdm KIT and other common treatments for the same condition?

Regulatory documents classify Vdm KIT as a Broad-Spectrum Antimicrobial Combination consisting of three distinct active ingredients. This specific composition—an antibiotic, an antifungal, and an antiprotozoal—is designed to provide simultaneous therapeutic action. The combination approach is a key distinguishing factor from treatments that contain only one active drug substance.


Q: Why do doctors prescribe a 'KIT' instead of just a single tablet?

The 'KIT' format is officially described as a co-packaged therapeutic regimen necessary to manage specific polymicrobial conditions. The central purpose is to deliver the three different drug components simultaneously. This strategy ensures comprehensive and focused antimicrobial coverage against a mix of bacterial, fungal, and protozoal threats.


Q: What happens if I miss a step or delay one part of the Vdm KIT regimen?

Official guidance emphasizes that the regimen's success is dependent upon rigid adherence to the administration protocol and completing the single course of treatment. The instructions for a missed dose in a fixed-course regimen are generally to not double the dose and to continue with the regular schedule. Guidance on a specific situation requires consultation with a medical professional.


Q: Are there any common foods or drinks that should be completely avoided while using Vdm KIT?

Regulatory documents strictly require the avoidance of alcohol/ethanol during therapy and for at least two days after the treatment course is finished due to the Secnidazole component. Additionally, certain antacids containing aluminum or magnesium should be taken at least two hours apart from the Azithromycin component to avoid affecting its absorption.


Q: Does Vdm KIT interact with common pain relievers like ibuprofen or acetaminophen?

Official regulatory interaction tables list specific drugs that have documented effects with Vdm KIT, such as anticoagulants and certain cardiac drugs. The labels do not explicitly list common over-the-counter pain relievers like ibuprofen or acetaminophen as formally restricted interactions. Regulatory labeling advises patients to discuss all concurrent medications being taken with their prescriber.


Q: Does Vdm KIT interact with hormonal birth control?

While the combination regimen's core label may not explicitly detail this interaction, public health guidance for one component, Fluconazole, generally indicates no restriction for use with combined hormonal contraceptives. Because the regimen can modify the plasma concentrations of certain medicines, official guidance often recommends patients discuss potential interactions with a healthcare provider.


Q: Can Vdm KIT be used if a person has diabetes?

Diabetes itself is not listed as an absolute contraindication in the official eligibility profile. However, one of the components, Fluconazole, is known to potentially interact with certain oral diabetes medications (hypoglycemics). The potential for this interaction means patients with this underlying condition are typically managed with caution and close monitoring.


Q: Is Vdm KIT available over-the-counter in any country?

According to regulatory documents, Vdm KIT is classified as a prescription-only (Rx) medication. It is a single-course regimen used to manage complex polymicrobial conditions, and as such, it is not designated for over-the-counter use in official documentation.


Q: Does the efficacy of Vdm KIT depend on a person's weight?

The regulatory documents define Vdm KIT as a fixed adult dose consisting of specified component strengths. The label is structured as a single, fixed-strength course for adult use. Official prescribing information does not provide weight-based dosing instructions for the regimen.


Q: Is Vdm KIT known by any other name?

Vdm KIT contains the three active ingredients: Azithromycin, Fluconazole, and Secnidazole. Due to this fixed-dose composition, it is known generically by the names of its components. The kit itself may be sold under various proprietary brand names in different regions globally.


Q: Is it common to feel very tired after using Vdm KIT?

Official adverse reaction lists often categorize the most common effects as Gastrointestinal or Nervous System disorders (e.g., headache and dizziness). While fatigue or tiredness may be reported in post-market data, it is typically not listed among the most frequently observed side effects in the primary regulatory documentation for the combination.


Q: Is Vdm KIT safe to use if I have an existing kidney problem?

Official regulatory documents state that the use of Vdm KIT is strictly contraindicated in patients who have severe renal (kidney) impairment. For individuals with less severe kidney disease, the regulatory label advises that substantial caution and professional supervision are required.


Q: Is Vdm KIT considered a narcotic or controlled substance?

Vdm KIT is officially classified as a Broad-Spectrum Antimicrobial Combination. Its components are an antibiotic, an antifungal, and an antiprotozoal agent. None of the active ingredients—Azithromycin, Fluconazole, or Secnidazole—are classified by government agencies as a narcotic or a controlled substance.


Q: Why do people sometimes misunderstand how Vdm KIT is supposed to be used?

The administration protocol for Vdm KIT can be complex because it involves taking three distinct drug components simultaneously, each with different instructions. For example, some components require specific timing relative to meals, and strict substance avoidance (like alcohol) is required, which necessitates careful adherence to all regulatory rules.


Q: Are there different versions or strengths of Vdm KIT?

The Vdm KIT is approved as a fixed-dose therapeutic regimen with a standard, single strength for all its components. The official regulatory label typically describes only this specific composition: 1 gram of Azithromycin, 150 mg of Fluconazole, and 2 grams of Secnidazole.


Q: Is it true that Vdm KIT can cause changes in vision?

Official side effect listings primarily focus on more common effects like dizziness and gastric upset. However, the macrolide antibiotic component, Azithromycin, has been historically associated in some regulatory reports with temporary vision changes in rare cases. Official guidance recommends patients note and report any observed changes in their condition.


Q: Is Vdm KIT suitable for people over the age of 65?

The regulatory label advises that use in older adults with underlying medical conditions requires caution and professional supervision. This is partly due to the fact that the documented risk of certain heart rhythm abnormalities (QT prolongation) associated with the components may be heightened in this age group.


Q: Has Vdm KIT been studied in children or adolescents?

Official documents clearly state that Vdm KIT is not recommended for use in children (pediatric patients). This restriction is based on the fact that its safety and efficacy have not been established in this younger population, meaning there is a lack of foundational studies and regulatory approval for pediatric use.


Q: Is Vdm KIT used for any conditions other than the primary one it treats?

Regulatory documents provide a specific, documented therapeutic indication for which Vdm KIT is approved. Official information defines its purpose for managing specific complex or polymicrobial conditions. Any use outside of this established indication is considered off-label and is not supported by the product label.


Q: What are the official warnings about driving or operating machinery while using Vdm KIT?

The official label includes specific warnings that Vdm KIT may cause dizziness and other effects that can impair mental function. Therefore, regulatory advice is to avoid driving or operating machinery until a person is certain of how the medication affects them.


Q: Why does Vdm KIT have a black box warning, if it does?

Official regulatory documents for the components describe serious documented risks, including Severe Hepatotoxicity (liver injury) and QT Interval Prolongation (a heart rhythm abnormality). These risks are treated with the highest level of explicit warning in the regulatory labeling.


Q: Can Vdm KIT be used during pregnancy or while breastfeeding?

Regulatory documents generally state that Vdm KIT is not recommended for use in pregnant women (especially during the first trimester) and breastfeeding women. Official labels state that decisions regarding use during these periods require the guidance of a physician.


Q: What are the most common reasons Vdm KIT might not work for someone?

Reasons for potential treatment failure are often related to non-adherence, as the regimen's success is dependent upon rigid adherence to the administration protocol. Treatment failure can also occur if the infection is caused by pathogens that are naturally not susceptible to the combination of Azithromycin, Fluconazole, and Secnidazole.


Q: Are there specific symptoms that mean Vdm KIT should be stopped immediately?

Regulatory documents explicitly list serious adverse reactions that require immediate attention. These include signs of Severe Hepatotoxicity (such as jaundice), Severe Cutaneous Adverse Reactions (such as a severe rash), and symptoms of Severe Cardiac Disorders (such as passing out or a very fast heartbeat).


Q: Is Vdm KIT generally well-tolerated?

Based on clinical trials, Vdm KIT is generally found to be acceptable to most patients. The main Phase 3 trial reported a low incidence of serious adverse events, with the most frequently reported side effects being mild gastric upset and temporary dizziness among participants.


Q: Does Vdm KIT interact with any common herbal supplements?

Regulatory guidance often notes that herbal supplements and other non-prescription remedies are not tested in the same manner as prescription drugs for their effects on Vdm KIT. Patients are generally advised in official guidance to inform their physician of all herbal remedies, vitamins, or supplements being taken.


Q: Why are there so many steps involved in using Vdm KIT?

The complexity of the administration is required because the three distinct drug components have different needs for optimal use. For example, the Azithromycin component must be taken separately from meals for better absorption, while the other two components are often advised to be taken with or after food to aid tolerability.

How should Vdm KIT be stored and disposed of?

How to Store and Dispose of Vdm KIT

The storage and disposal of Vdm KIT (Azithromycin, Fluconazole, Secnidazole Tablets) must strictly follow official regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store below 30 C (86 F) in a cool, dry place.
Protection Must be protected from light and moisture.
Packaging Keep in the original container or pack, and keep tightly closed.
Safety Must be stored out of the reach of children and pets.

Disposal Instructions

Unused or expired Vdm KIT must be disposed of according to local regulations and official instructions. Follow community drug take-back guidelines or pharmacy collection points to ensure proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vdm KIT found in:

A-Z Index: